HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: A systematic review and meta-analysis

Mohamad A. Meybodi, Wenhao Cao, Leo Luznik, Asad Bashey, Xu Zhang, Rizwan Romee, Wael Saber, Mehdi Hamadani, Daniel J Weisdorf, Haitao Chu, Armin Rashidi

Research output: Contribution to journalArticle

Abstract

HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ∼50% lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95% CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.

Original languageEnglish (US)
Pages (from-to)2581-2585
Number of pages5
JournalBlood Advances
Volume3
Issue number17
DOIs
StatePublished - Sep 10 2019

Fingerprint

Cell Transplantation
Graft vs Host Disease
Meta-Analysis
Cyclophosphamide
Confidence Intervals
Recurrence
Retrospective Studies
Mortality
Research

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

HLA-haploidentical vs matched-sibling hematopoietic cell transplantation : A systematic review and meta-analysis. / Meybodi, Mohamad A.; Cao, Wenhao; Luznik, Leo; Bashey, Asad; Zhang, Xu; Romee, Rizwan; Saber, Wael; Hamadani, Mehdi; Weisdorf, Daniel J; Chu, Haitao; Rashidi, Armin.

In: Blood Advances, Vol. 3, No. 17, 10.09.2019, p. 2581-2585.

Research output: Contribution to journalArticle

Meybodi, Mohamad A. ; Cao, Wenhao ; Luznik, Leo ; Bashey, Asad ; Zhang, Xu ; Romee, Rizwan ; Saber, Wael ; Hamadani, Mehdi ; Weisdorf, Daniel J ; Chu, Haitao ; Rashidi, Armin. / HLA-haploidentical vs matched-sibling hematopoietic cell transplantation : A systematic review and meta-analysis. In: Blood Advances. 2019 ; Vol. 3, No. 17. pp. 2581-2585.
@article{38857ab82e5a4f3295221526ce653e36,
title = "HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: A systematic review and meta-analysis",
abstract = "HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ∼50{\%} lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95{\%} confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95{\%} CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.",
author = "Meybodi, {Mohamad A.} and Wenhao Cao and Leo Luznik and Asad Bashey and Xu Zhang and Rizwan Romee and Wael Saber and Mehdi Hamadani and Weisdorf, {Daniel J} and Haitao Chu and Armin Rashidi",
year = "2019",
month = "9",
day = "10",
doi = "10.1182/bloodadvances.2019000614",
language = "English (US)",
volume = "3",
pages = "2581--2585",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "17",

}

TY - JOUR

T1 - HLA-haploidentical vs matched-sibling hematopoietic cell transplantation

T2 - A systematic review and meta-analysis

AU - Meybodi, Mohamad A.

AU - Cao, Wenhao

AU - Luznik, Leo

AU - Bashey, Asad

AU - Zhang, Xu

AU - Romee, Rizwan

AU - Saber, Wael

AU - Hamadani, Mehdi

AU - Weisdorf, Daniel J

AU - Chu, Haitao

AU - Rashidi, Armin

PY - 2019/9/10

Y1 - 2019/9/10

N2 - HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ∼50% lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95% CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.

AB - HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ∼50% lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95% CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.

UR - http://www.scopus.com/inward/record.url?scp=85072206849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072206849&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2019000614

DO - 10.1182/bloodadvances.2019000614

M3 - Article

C2 - 31484635

AN - SCOPUS:85072206849

VL - 3

SP - 2581

EP - 2585

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 17

ER -